Nick Shah

Scientist | Drug Discovery, Commercialization

Role: Scientist

Site: CDL-Vancouver

Stream: Health

Nick is a scientist and leader with extensive experience in leading teams that discover novel therapies for difficult drug targets. He currently leads the In Vitro Pharmacology group at DiCE Molecules where the team is working to discover and develop innovative therapies in immunology.

Previously, Nick was an early scientist at Flexus Biosciences where the team discovered Linrodostat (Phase III for immuno-oncology). He also worked with the FLX Bio (now RAPT Therapeutics) team to discover FLX475 (Phase I/II for immuno-oncology) and RPT193 (Phase I for atopic dermatitis). Throughout his career, he has been deeply involved in assay development for drug discovery while leading project teams and managing multiple lead discovery campaigns.

Nick completed his PhD at the University of Toronto and a postdoctoral fellowship at Stanford University.